Kukje Pharma Co., Ltd. (KRX:002720)

Market Cap	99.17B -1.2%
Revenue (ttm)	175.50B +12.2%
Net Income	5.70B +9.5%
EPS	280.00 +9.4%
Shares Out	20.36M
PE Ratio	17.39
Forward PE	n/a
Dividend	30.00 (0.63%)
Ex-Dividend Date	Mar 12, 2026

Volume	234,917
Average Volume	392,231
Open	4,820.00
Previous Close	4,785.00
Day's Range	4,820.00 - 4,940.00
52-Week Range	4,050.00 - 5,470.00
Beta	0.55
RSI	49.31
Earnings Date	Apr 2, 2026

About Kukje Pharma

Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAID...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 248
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 002720

Financial Performance

In 2025, Kukje Pharma's revenue was 175.50 billion, an increase of 12.16% compared to the previous year's 156.46 billion. Earnings were 5.70 billion, an increase of 9.46%.